Inactive Instrument

Meridian Bioscience, Inc.

VIVO

US5895841014

Medical Equipment, Supplies & Distribution

Meridian Bioscience: Fiscal Q3 Earnings Snapshot

August 05, 2022 at 08:18 am EDT

CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Friday reported a loss of $7.3 million in its fiscal third quarter.

On a per-share basis, the Cincinnati-based company said it had a loss of 16 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, were 17 cents per share.

The diagnostic test maker posted revenue of $67.8 million in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VIVO at https://www.zacks.com/ap/VIVO

Latest news about Meridian Bioscience, Inc.

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits	Apr. 10	CI
Meridian Bioscience, Inc. announced that it has received KRW 128.772575398 billion in funding	Nov. 29	CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 128.772575393 billion in funding	Nov. 21	CI
Meridian Bioscience, Inc. announced that it has received KRW 258.225164381 billion in funding from Columbus Holding Company	23-07-27	CI
Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex	23-07-25	CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding	23-06-11	CI
Meridian Bioscience, Inc. Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay	23-04-19	CI
Meridian Bioscience, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-09	CI
SD Biosensor, SJL Partners Acquire Meridian Bioscience	23-01-31	MT
Meridian Bioscience, Inc.(NasdaqGM:VIVO) dropped from NASDAQ Composite Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Healthcare Equipment Select Industry Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Composite 1500	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Global BMI Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P TMI Index	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 1000	23-01-31	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600 Health Care	23-01-31	CI
SD BioSensor, Inc and SJL Partners completed the acquisition of Meridian Bioscience, Inc. from Impactive Capital LP, BlackRock, Inc., The Vanguard Group, Inc, Royce & Associates, LP and others.	23-01-30	CI
DoubleVerify Holdings to Replace Meridian Bioscience in S&P SmallCap 600	23-01-26	MT
Meridian Bioscience Says Closing Date of Pending Merger With SD Biosensor, Others Pushed Back to Jan. 31	22-12-12	MT
Meridian Bioscience Fiscal Q4 Adjusted EPS, Revenue Decline	22-11-22	MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 Revenue $65.7M	22-11-22	MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 EPS $0.20	22-11-22	MT
Meridian Bioscience, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-22	CI
Meridian Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022	22-11-22	CI

Chart Meridian Bioscience, Inc.

Duration

Period

More charts

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-4.82%	182B
MEDTRONIC PLC	+1.38%	110B
BECTON, DICKINSON AND COMPANY	-2.82%	68.11B
DEXCOM, INC.	+0.69%	50.53B
CENCORA, INC.	+8.54%	44.8B
HOYA CORPORATION	+2.58%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+20.50%	32.25B
WEST PHARMACEUTICAL SERVICES, INC.	+1.72%	26.53B
TERUMO CORPORATION	+14.69%	25.02B

Other Medical Equipment, Supplies & Distribution

Meridian Bioscience, Inc.

Equities

VIVO

US5895841014

Medical Equipment, Supplies & Distribution

Meridian Bioscience: Fiscal Q3 Earnings Snapshot

Latest news about Meridian Bioscience, Inc.

Chart Meridian Bioscience, Inc.

Company Profile

Sector Other Medical Equipment, Supplies & Distribution